Venkatesh, Hemachandra <br/><br/>
Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.  [electronic resource] 

 -  Clinical lymphoma  Sep 2004 
 - 110-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1526-9655 
<br/><br/><label>Standard No.: </label>10.3816/clm.2004.n.017  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antimetabolites, Antineoplastic--therapeutic use<br/>Bone Marrow Transplantation<br/>Deoxycytidine--analogs & derivatives<br/>Disease Progression<br/>Drug Resistance, Neoplasm<br/>Female<br/>Hodgkin Disease--drug therapy<br/>Humans<br/>Male<br/>Middle Aged<br/>Recurrence<br/>Time Factors<br/>Treatment Outcome<br/>Gemcitabine